Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCBMT1380


Chronic GVHD Response Measures Validation

Principal Investigator(s)

Madan Jagasia


  • Protocol No. VICCBMT1380
  • Open Date: 02/05/2014
  • Staging: N/A
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: To develop and validate endpoint measures that can accurately determine whether patients are responding to treatment for chronic GVHD.
  • Disease Sites: Hematologic
  • Therapies: None Specified
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01902576
  • Secondary Protocol No: Not Specified


Patients with chronic graft-versus-host disease (GVHD) are being asked to take part in this study. In this study we want to know: how people with chronic GVHD do over several years, and the best ways to measure whether peoples chronic GVHD is getting better or worse.


Ages Eligible for Study:7 Years to 99 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No


Inclusion Criteria:
• Age 7 years or older
• Prior first allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis.
• Diagnosis of chronic GVHD according to the criteria of the diagnosis and scoring group of the NIH consensus conference (Patient must have at least one diagnostic manifestation of chronic GVHD or one distinctive manifestation with pathological confirmation of the diagnosis. Concurrent acute GVHD manifestations will be allowed as long as at least one classic chronic manifestation is present.)
• Initiation of a new systemic treatment for chronic GVHD in the past 4 weeks or anticipated within the next 4 weeks. Systemic treatment is defined as any medication or intervention that has intended systemic effects, including extracorporeal photopheresis, regardless of prior lines of therapy or prior treatment with the agent(s). If a patient is restarting a treatment to which they were previously exposed, they must have been off of it for at least 4 weeks before restarting.
• No evidence of persistent or progressive malignancy at the time of enrollment
• Evaluation at the transplant center at the time of study enrollment, and agreement to be re-evaluated at the transplant center up to four subsequent times: at 3 months, 6 months, and 18 months after enrollment and once if another treatment is added for chronic GVHD.
• Signed, informed consent
Exclusion Criteria:
• Inability to comply with study procedures
• Complete resolution of chronic GVHD at the time of enrollment (patient must have some measurable chronic GVHD activity)